Clinical Trials Logo

Small Lymphocytic Leukemia clinical trials

View clinical trials related to Small Lymphocytic Leukemia.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04189952 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

Start date: September 22, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test a combination treatment of acalabrutunib when given together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) to evaluate if it will be able to improve durable responses and cure some patients.

NCT ID: NCT02361346 Terminated - Clinical trials for Diffuse Large B Cell Lymphoma

Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL

MT-3724NHL001
Start date: February 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of MT-3724 in subjects with relapsed or refractory B-Cell NHL or relapsed and refractory CLL (Part 1 only) and relapsed and refractory DLBCL (Part 2 and Part 3). Part 3 evaluates the efficacy of MT-3724.

NCT ID: NCT00543114 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL

Start date: October 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety of lenalidomide (revlimid) in combination with fludarabine and rituximab and to determine the highest dose of lenalidomide that can safely be given in that combination. Lenalidomide is a drug that alters the immune system and may also interfere with the the development of tiny blood vessels that help support tumor growth. Lenalidomide is approved by the FDA for the treatment of two different blood cancers called myelodysplastic syndrome and multiple myeloma. Lenalidomide has also been studied in subjects with relapsed CLL. In this research study we are adding lenalidomide to a well-established initial therapy for CLL/SLL.